GlassScriptPhysician profile
Saulat Mushtaq
NPI 1518080605
$5,886.29
in general payments reported to CMS, 2019-2025
26 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $949 · 2021: $827 · 2022: $411 · 2023: $1,053 · 2024: $927 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,160 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.16 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,892.32 | 2020-2025 | |
| Amgen INC. | $473.56 | 2019-2025 | Tavneos, Otezla, Krystexxa |
| Novartis Pharmaceuticals Corporation | $452.29 | 2019-2025 | |
| Janssen Biotech, INC. | $416.28 | 2020-2024 | Tremfya |
| Ucb, INC. | $377.40 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $373.08 | 2020-2024 | Acthar |
| Lilly USA, LLC | $348.30 | 2019-2025 | Taltz |
| Pfizer INC. | $295.43 | 2020-2025 | |
| Celgene Corporation | $179.53 | 2019 | |
| Genzyme Corporation | $167.19 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $159.67 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $149.70 | 2022-2025 | Saphnelo |
| Allergan, INC. | $124.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.87 | 2020-2024 | Cyltezo, Ofev |
| Sandoz INC. | $79.70 | 2023-2024 | Hyrimoz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $77.46 | 2019-2025 | Benlysta, Nucala |
| Alexion Pharmaceuticals, INC. | $37.37 | 2021-2025 | Strensiq |
| Medexus Pharma, INC. | $29.61 | 2020 | |
| Organon LLC | $26.72 | 2025 | Hadlima |
| Kyowa Kirin, INC. | $20.57 | 2024 | Crysvita |
| Mallinckrodt Enterprises LLC | $19.54 | 2019 | |
| Genentech USA, INC. | $15.51 | 2023 | Erivedge |
| Philips North America LLC | $15.37 | 2023 | |
| Ani Pharmaceuticals, INC. | $13.70 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $13.42 | 2023 | Krystexxa |
| Gilead Sciences, INC. | $12.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saulat Mushtaq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.